QPPV.COM KNOWLEDGE ASSESSMENT

Designated Medical Events (DMEs) in Pharmacovigilance: A Practical Guide to Signal Detection

Test your understanding of the concepts covered by Designated Medical Events (DMEs) in Pharmacovigilance: A Practical Guide to Signal Detection.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A dashboard reports the number of DME alerts as the number of validated signals. What is the main methodological problem?

DME alerts cannot be counted because the list is not comprehensive. Only statistically disproportionate reports may be included in signal metrics. DME alerts should be counted as regulatory recommendations rather than signals. The dashboard collapses distinct stages: an alert or observation is not equivalent to a validated signal.

Question 2 of 10 Which statement best describes how DME surveillance relates to disproportionality analysis?

DME surveillance replaces disproportionality analysis for all events on the DME list. Disproportionality analysis is required before any DME report can be reviewed. They are complementary approaches: one prioritises selected events for clinical review, while the other identifies reporting patterns relative to a comparator. A DME report should be reviewed only if both methods identify the same product-event combination.

Question 3 of 10 A company’s procedure treats every DME-coded report as a serious case without separately applying the applicable seriousness criteria. What is the principal concern?

It conflates signal-detection prioritisation with the distinct ICSR seriousness assessment. It prevents the company from using MedDRA for signal detection. It is required only when the event is also statistically disproportionate. It incorrectly assumes that all serious cases are causal.

Question 4 of 10 Which statement best describes the relationship between a DME flag and signal prioritisation?

A DME flag completes signal prioritisation and removes the need for signal validation. A DME flag establishes the regulatory priority of the product over other safety issues. A DME flag is a detection-priority mechanism; later signal-management steps determine validation and further prioritisation. A DME flag is used only after a signal has already been validated.

Question 5 of 10 A single, well-documented DME case has a plausible chronology and no evident alternative cause, but no corroborating cases have yet been found. Which conclusion is most defensible?

One case always constitutes a validated signal if the event is rare. The case cannot be considered further until a minimum number of reports is reached. The case may justify further assessment, but there is no automatic one-case-equals-signal rule. The absence of other cases proves that the reported association is coincidental.

Question 6 of 10 Which set of questions most directly supports a case-level assessment of whether a DME report is plausibly related to a suspect medicine?

Was the event adequately confirmed, was its timing compatible, and are there credible alternative explanations? Does the event appear on the DME list, and was the ICSR received within the expected reporting period? Is the report statistically disproportionate, and does the product have a current marketing authorisation? Was the reaction classified as serious, and does the reporter consider the medicine responsible?

Question 7 of 10 Which interpretation best distinguishes a DME from an IME?

A DME determines whether an ICSR meets a regulatory seriousness criterion, whereas an IME determines whether causality is established. An IME is used only for signal detection, whereas a DME is used only for aggregate analysis. An IME supports medical-importance and seriousness assessment, whereas a DME provides a selective signal-detection safety net. A DME and an IME have the same purpose, but use different MedDRA terminology.

Question 8 of 10 Which governance measure best supports a reliable DME surveillance process?

Define how matches are detected, who reviews them, how decisions are documented, and how the list and configuration are maintained. Use the DME list without change control so that results remain consistent over time. Record only DME alerts that become validated signals, since other reviews have no operational value. Set one universal review deadline for every organisation and every DME case.

Question 9 of 10 Why should an organisation align its DME configuration with the MedDRA version used for analysis?

MedDRA version alignment determines whether a case meets seriousness criteria. A DME list is valid only when every event is coded as a MedDRA high-level term. Version alignment makes clinical review unnecessary for matched cases. Terminology changes can affect how terms are represented or identified, potentially altering which cases are surfaced.

Question 10 of 10 A DME-coded report describes a diagnosis that is not supported by the clinical narrative or available investigations. What should the reviewer do first?

Accept the coded term as sufficient evidence because the DME list is selective. Check whether the underlying source information supports the coded medical concept. Validate the signal and request diagnostic confirmation afterward. Remove the report from all pharmacovigilance analyses.

QPPV.com

Designated Medical Events (DMEs) in Pharmacovigilance: A Practical Guide to Signal Detection

Cookie Settings